Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

1.15
-0.4000-25.81%
Pre-market: 1.04-0.1100-9.57%05:41 EDT
Volume:9.94M
Turnover:16.20M
Market Cap:3.89M
PE:-0.59
High:2.16
Open:1.59
Low:1.06
Close:1.55
52wk High:9.59
52wk Low:1.06
Shares:3.39M
Float Shares:2.25M
Volume Ratio:179.37
T/O Rate:442.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9469
EPS(LYR):-2.0691
ROE:-113.96%
ROA:-66.91%
PB:0.93
PE(LYR):-0.56

Loading ...

Amex Halt Add Info Lst 1.560000

THOMSON REUTERS
·
Yesterday

Kairos Pharma Reports Strong Interim Results for ENV-105 Combo

TIPRANKS
·
Yesterday

Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105

TIPRANKS
·
Yesterday

Kairos Pharma Posts Interim Phase 2 Data Showing ENV-105 Plus Apalutamide Extends Median PFS to 17.7 Months in mCRPC Trial

Reuters
·
Yesterday

Kairos Pharma - Modifies Phase 2 Protocol to Enroll Patients Earlier in Disease Progression

THOMSON REUTERS
·
Yesterday

Kairos Pharma - Targets Phase 2 Trial Completion in or Before Q4 2027

THOMSON REUTERS
·
Yesterday

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of Env-105 in Metastatic Prostate Cancer

THOMSON REUTERS
·
Yesterday

Kairos Pharma’s Bhowmick Presents at Discovery on Target Drug Discovery Conference

Reuters
·
Sep 23

Kairos Pharma Highlights Clinical Strategy in Investor Presentation

TIPRANKS
·
Sep 15

Kairos Pharma CEO John Yu Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 09

Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings
·
Aug 24

Kairos Pharma to Conduct 1-for-7 Reverse Stock Split

MT Newswires Live
·
Aug 22

Kairos Pharma Announces 1-for-7 Reverse Stock Split

THOMSON REUTERS
·
Aug 22

Kairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence

TIPRANKS
·
Aug 14

Kairos Pharma Q2 FY26 Net Loss Narrows to $1.39 Million; Revenue Flat at no Revenue

Reuters
·
Aug 13

Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12

TIPRANKS
·
Jul 28

Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)

TIPRANKS
·
Jul 24

Kairos Pharma, Bayer partner on prostate cancer therapy

TIPRANKS
·
Jul 22

Kairos Pharma Partners with Bayer to Test Env-105 with Xofigo in Metastatic Prostate Cancer

Reuters
·
Jul 22

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance Xofigo Activity in Metastatic Prostate Cancer

THOMSON REUTERS
·
Jul 22